Predict your next investment

Corporation
HEALTHCARE | Drug Development
sangart.com

See what CB Insights has to offer

Founded Year

1998

Stage

Series G - II | Dead

Total Raised

$180.36M

Last Raised

$50.77M

About Sangart

Sangart is a biopharmaceutical company focused on oxygen-therapeutic agents, providing products to patients in need. Sangart was founded in 1998 based on discoveries arising from over two decades of research in red blood cell substitutes and the mechanisms of oxygen transport by cell-free hemoglobin solutions.

Sangart Headquarter Location

6175 Lusk Boulevard Suite 104

San Diego, California, 92121,

United States

858-450-2400

Latest Sangart News

This Seattle biotech CEO will soon be ousted from his job

Apr 3, 2015

This Seattle biotech CEO will soon be ousted from his job Apr 3, 2015, 2:12pm PDT Send this to a friend Thank you for sharing. Your email has been sent. Email address of friend (insert comma between multiple addresses): Your email address: Email  |  Twitter The man tapped four months ago to lead one of Seattle's newest public companies once a ran a company that, a few years ago, disappeared without a trace. Brian O'Callaghan was appointed the new CEO of Acucela , which makes treatments for eye diseases, only a few months ago after founder Dr. Ryo Kubota was ousted from the CEO spot in December. Now, Kubota is fighting to get his company back. The Seattle biotech will soon be turned completely upside down when Kubota and the other largest shareholder, SBI Holdings, vote to replace four board members. O'Callaghan, who was COO, took over as CEO just as the proxy battle begun. Acucela wouldn't provide comment about O'Callaghan. According to his LinkedIn profile, though, he has a background at several San Diego-area biotech companies. O'Callaghan was CEO of Sangart , a San Diego biotech company. The company apparently went "missing in action" in 2013 after burning $260 million on research and development, according to biotech news site FierceBiotech . The biotech news site reported that the company's website went dark immediately after the drug trial failed. Google searches turn up no website for Sangart and there seems to be no trace of the company since then. That happened under O'Callaghan's leadership after the company's drug, which was designed to treat trauma patients, failed in early trials. "About all that [Sangart's] sole big investor will do is point to financial reports stating they've cut off their commitment to provide financial support to Sangart," FierceBiotech wrote, "after the last big trial ended in failure and that company execs have been scouting for a fresh source of financing. " Page 1

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sangart

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sangart is included in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Sangart Patents

Sangart has filed 13 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/17/2014

11/3/2020

Amines, Proteins, Molecular biology, Biotechnology, Rare diseases

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

3/17/2014

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/3/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Amines, Proteins, Molecular biology, Biotechnology, Rare diseases

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sangart Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sangart Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.